Taha Sen

448 total citations
12 papers, 301 citations indexed

About

Taha Sen is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Nephrology. According to data from OpenAlex, Taha Sen has authored 12 papers receiving a total of 301 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Endocrinology, Diabetes and Metabolism, 6 papers in Surgery and 4 papers in Nephrology. Recurrent topics in Taha Sen's work include Diabetes Treatment and Management (9 papers), Pancreatic function and diabetes (4 papers) and Chronic Kidney Disease and Diabetes (4 papers). Taha Sen is often cited by papers focused on Diabetes Treatment and Management (9 papers), Pancreatic function and diabetes (4 papers) and Chronic Kidney Disease and Diabetes (4 papers). Taha Sen collaborates with scholars based in Netherlands, Australia and United States. Taha Sen's co-authors include Hiddo J.L. Heerspink, Michael K. Hansen, Bruce Neal, Clare Arnott, Brendon L. Neuen, Vlado Perkovic, Kenneth W. Mahaffey, Chirag R. Parikh, Steven G. Coca and Jingwei Li and has published in prestigious journals such as Diabetes Care, Cell Metabolism and Diabetes.

In The Last Decade

Taha Sen

12 papers receiving 299 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Taha Sen Netherlands 8 203 116 101 73 37 12 301
Yingqiong Peng China 4 188 0.9× 97 0.8× 127 1.3× 95 1.3× 17 0.5× 4 278
Leslie Cham Canada 9 153 0.8× 105 0.9× 92 0.9× 49 0.7× 32 0.9× 11 252
Lubin Xu China 7 225 1.1× 177 1.5× 108 1.1× 114 1.6× 81 2.2× 17 399
Harindra Rajasekeran Canada 5 278 1.4× 97 0.8× 143 1.4× 101 1.4× 36 1.0× 6 320
Shingo Urate Japan 8 119 0.6× 68 0.6× 46 0.5× 53 0.7× 39 1.1× 19 262
Sho Sugahara Japan 5 173 0.9× 65 0.6× 106 1.0× 92 1.3× 26 0.7× 11 316
June K.Y. Li China 9 202 1.0× 110 0.9× 97 1.0× 114 1.6× 21 0.6× 12 433
Domenica A. McCarthy Australia 8 130 0.6× 77 0.7× 84 0.8× 90 1.2× 16 0.4× 15 303
Chien‐Ting Pan Taiwan 12 320 1.6× 82 0.7× 258 2.6× 69 0.9× 38 1.0× 29 490
Toru Kagawa Japan 7 61 0.3× 184 1.6× 74 0.7× 81 1.1× 23 0.6× 9 361

Countries citing papers authored by Taha Sen

Since Specialization
Citations

This map shows the geographic impact of Taha Sen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Taha Sen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Taha Sen more than expected).

Fields of papers citing papers by Taha Sen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Taha Sen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Taha Sen. The network helps show where Taha Sen may publish in the future.

Co-authorship network of co-authors of Taha Sen

This figure shows the co-authorship network connecting the top 25 collaborators of Taha Sen. A scholar is included among the top collaborators of Taha Sen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Taha Sen. Taha Sen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Sen, Taha, Wenjun Ju, Viji Nair, et al.. (2023). Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes. Kidney International. 104(4). 828–839. 16 indexed citations
2.
Curovic, Viktor Rotbain, Niels Jongs, Emilie H. Zobel, et al.. (2023). Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial. Diabetes Care. 46(3). 593–601. 13 indexed citations
3.
Sen, Taha, Bruce Neal, Maarten J. Bijlsma, et al.. (2022). Mechanisms of action of the sodium‐glucose cotransporter‐2 ( SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial. Diabetes Obesity and Metabolism. 24(10). 1950–1956. 18 indexed citations
4.
Sen, Taha, Peter J. Greasley, David Z.I. Cherney, et al.. (2022). Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND. Diabetes Obesity and Metabolism. 24(8). 1578–1587. 26 indexed citations
5.
Schechter, Meir, Taha Sen, Priya Vart, et al.. (2022). Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS. Diabetes Care. 45(11). 2644–2652. 33 indexed citations
6.
Sen, Taha & Hiddo J.L. Heerspink. (2021). A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors. Cell Metabolism. 33(4). 732–739. 106 indexed citations
7.
Sen, Taha, Jingwei Li, Brendon L. Neuen, et al.. (2021). Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. Diabetologia. 64(10). 2147–2158. 50 indexed citations
8.
Sen, Taha, Clare Arnott, Bruce Neal, et al.. (2021). Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology. 17(2). 251–259. 34 indexed citations
9.
Sen, Taha, Jingwei Li, Brendon L. Neuen, et al.. (2020). The SGLT2 Inhibitor Canagliflozin Reduces the Plasma Markers TNFR-1, TNFR-2, and KIM-1 in the CANVAS Trial. Journal of the American Society of Nephrology. 31(10S). 343–343. 1 indexed citations
10.
11.
Sen, Taha, Jingwei Li, Brendon L. Neuen, et al.. (2020). Associations Between TNFR-1, TNFR-2, and KIM-1 with Kidney and Cardiovascular Outcomes: Results from the CANVAS Trial. Journal of the American Society of Nephrology. 31(10S). 338–338. 1 indexed citations
12.
Sen, Taha, Jingwei Li, Bruce Neal, et al.. (2020). 1098-P: Biomarkers of Tubular Injury and Effects of Canagliflozin in the CANVAS Trial. Diabetes. 69(Supplement_1). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yingqiong Peng Breakdown of academic impact, for papers by Leslie Cham Breakdown of academic impact, for papers by Lubin Xu Breakdown of academic impact, for papers by Harindra Rajasekeran Breakdown of academic impact, for papers by Shingo Urate Breakdown of academic impact, for papers by Sho Sugahara Breakdown of academic impact, for papers by June K.Y. Li Breakdown of academic impact, for papers by Domenica A. McCarthy Breakdown of academic impact, for papers by Chien‐Ting Pan Breakdown of academic impact, for papers by Toru Kagawa
Rankless by CCL
2026